Obesity Management

Navitus Health Solutions conducted a survey of 2000 US adults who have been taking glucagon-like peptide-1 therapies for the past 2 years.

Novo Nordisk’s CagriSema drives 23% weight loss in REDEFINE 4 but misses noninferiority compared with tirzepatide, shaping the next wave of obesity drugs.

With expanding scopes of practice, there has never been a better time to introduce or expand clinical services that improve patient outcomes.

Buchanan Ingersoll & Rooney’s Dae Lee, PharmD, Esq, CPBS, and Lucas Morgan, Esq, provide a timely legal update regarding GLP-1 distribution and compounding.

Pfizer's phase 2b study reveals promising results for its monthly GLP-1 therapy, enhancing weight loss and medication adherence in obesity management.

Novo Nordisk's CagriSema shows significant improvements in blood glucose control and weight loss for type 2 diabetes patients in recent trial results.

GLP-1 therapies gain popularity, but patient adherence struggles due to fragmented support and emotional barriers.

The company announces that the pill is now available at over 70,000 pharmacies across the country.

Orforglipron shows promise in maintaining weight loss for those transitioning from injectable GLP-1 therapies, offering a convenient oral alternative.

With brand-new challenges and opportunities in the GLP-1 space and obesity management as a whole, here are the top developments from the past year.

The landmark oral formulation of the popular weight loss drug is set to launch in early 2026.

Pediatric obesity rates surge, prompting a debate on GLP-1 agonists versus traditional treatments, highlighting efficacy, risks, and long-term implications.

With evidence of antiobesity properties in human trials, berberine could be an OTC phytotherapeutic option for weight loss.

Eloralintide shows promising weight loss results in a phase 2 trial, offering a new option for obesity management with improved tolerability.

A secondary analysis of the obesity-fertility lifestyle intervention program explored how it impacted the behavior of women with obesity and subfertility.

Oral semaglutide 25 mg shows significant benefits in weight loss and cardiovascular health for patients with obesity, enhancing overall well-being.

Eli Lilly and Walmart collaborate to enhance access to Zepbound for obesity management, offering direct-to-consumer pricing and nationwide pharmacy pickup.

A study reveals that lower baseline BMI and early weight loss with liraglutide enhance significant weight loss outcomes in patients with type 2 diabetes.

Pharmacists can help patients maintain muscle mass, meet their protein needs, and prevent nutritional deficiencies through evidence-based guidance that supports better overall health.

As GLP-1 popularity, use, and price continues to rise, pharmacy industry stakeholders are attempting to guide pharmacists and patients around the complexities of this drug class.

In part 3 of our interview with Rae McMahan, she explores her role at Prescryptive Health and how she’s helping pharmacy stakeholders navigate complex GLP-1 prescription drug benefits.

Through her work as senior vice president of payor solutions at Prescryptive Health, Rae McMahan shares insights into how increased GLP-1 popularity and costs impact pharmacies.

Rae McMahan, senior vice president of payor solutions at Prescryptive Health, discusses GLP-1 access, advertising, and the challenges that often accompany this drug class.

In hospitalized patients with obesity, researchers conduct a study detailing how electronic clinical support helps participants optimize their treatment regimens.

Orforglipron shows results in weight loss and diabetes management, offering a new oral treatment option for patients.